Jacobs Levy Equity Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,817	Closed	-$56K	–	1059
2018 Q4	$56K	Buy	3,817 +1,902	+99%	+$77.6K	﹤0.01%	955
2018 Q3	$134K	Sell	1,915 -825	-30%	-$62.6K	﹤0.01%	956
2018 Q2	$203K	Buy	2,740 +2,074	+311%	+$185K	﹤0.01%	953
2018 Q1	$63K	Buy	666 +194	+41%	+$33.3K	﹤0.01%	975
2017 Q4	$61K	Buy	+472	New	+$44.2K	﹤0.01%	964
2016 Q4	–	Sell	-469	Closed	-$72K	–	1072
2016 Q3	$72K	Sell	469 -944	-67%	-$133K	﹤0.01%	978
2016 Q2	$163K	Sell	1,413 -114	-7%	-$12.6K	﹤0.01%	1043
2016 Q1	$173K	Buy	+1,527	New	+$231K	﹤0.01%	986
2015 Q1	–	Sell	-199	Closed	-$107K	–	893
2014 Q4	$107K	Buy	+199	New	+$89.7K	﹤0.01%	780

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's VIRX Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2019, closing a stake of 3,817 shares — an estimated $56K sold.

Jacobs Levy Equity Management first reported a position in VIRX in Q4 2014 and held it in 9 quarters. The position peaked at $203K in Q2 2018. 44 funds tracked by Wall St. Rank hold VIRX as of Q1 2019.

Jacobs Levy Equity Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 3,817 Viracta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $56K.
Jacobs Levy Equity Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 9 quarters.
Jacobs Levy Equity Management's Viracta Therapeutics, Inc. Common Stock position peaked at $203K in Q2 2018.
44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.